Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a benzamide derivative, reversible inhibitor of monoamine oxidase type A used for the treatment of depression and social anxiety disorder. Oral administration in two daily doses.
It is excreted into breast milk in a clinically non-significant amount. (Buist 1998, Pons 1990)
No clinical untoward effects on the physical and psychomotor development of the infants at both short and long-term basis. (Taylor 2009, Buist 1998)
Some reports of galactorrhea and increased prolactin have been described. (Dunn 1998, Juruena 1997, Nair 1993)
Because there is less published experience with this drug than with others, an alternative known to be safer should be preferred, especially during the neonatal period and in the event of prematurity.
See below the information of this related product: